- Home
- FHN vs LEGN Comparison
FHN vs LEGN Comparison
Compare FHN & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHN
- LEGN
- Stock Information
- Founded
- FHN 1864
- LEGN 2014
- Country
- FHN United States
- LEGN United States
- Employees
- FHN N/A
- LEGN N/A
- Industry
- FHN Major Banks
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- FHN Finance
- LEGN Health Care
- Exchange
- FHN Nasdaq
- LEGN Nasdaq
- Market Cap
- FHN 11.0B
- LEGN 6.7B
- IPO Year
- FHN N/A
- LEGN 2020
- Fundamental
- Price
- FHN $22.77
- LEGN $34.45
- Analyst Decision
- FHN Buy
- LEGN Strong Buy
- Analyst Count
- FHN 17
- LEGN 12
- Target Price
- FHN $23.32
- LEGN $73.36
- AVG Volume (30 Days)
- FHN 11.4M
- LEGN 1.1M
- Earning Date
- FHN 10-15-2025
- LEGN 11-11-2025
- Dividend Yield
- FHN 2.66%
- LEGN N/A
- EPS Growth
- FHN 28.04
- LEGN N/A
- EPS
- FHN 1.55
- LEGN N/A
- Revenue
- FHN $3,083,000,000.00
- LEGN $796,838,000.00
- Revenue This Year
- FHN $10.95
- LEGN $70.75
- Revenue Next Year
- FHN $3.68
- LEGN $52.47
- P/E Ratio
- FHN $14.58
- LEGN N/A
- Revenue Growth
- FHN 4.62
- LEGN 74.75
- 52 Week Low
- FHN $14.83
- LEGN $27.34
- 52 Week High
- FHN $23.08
- LEGN $52.15
- Technical
- Relative Strength Index (RSI)
- FHN 56.00
- LEGN 44.99
- Support Level
- FHN $21.94
- LEGN $32.70
- Resistance Level
- FHN $23.08
- LEGN $34.71
- Average True Range (ATR)
- FHN 0.47
- LEGN 1.24
- MACD
- FHN -0.03
- LEGN 0.11
- Stochastic Oscillator
- FHN 65.53
- LEGN 47.16
About FHN First Horizon Corporation
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer & Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer & Wealth. The Commercial, Consumer & Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.